Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D07LBQ
|
||||
| Former ID |
DIB002845
|
||||
| Drug Name |
GSK2398852
|
||||
| Synonyms |
2398852
|
||||
| Drug Type |
Antibody
|
||||
| Target and Pathway | |||||
| Target(s) | Serum amyloid P-component | Target Info | [524198], [531012] | ||
| Reactome | Amyloid formation | ||||
| WikiPathways | Human Complement System | ||||
| Amyloids | |||||
| References | |||||
| Ref 524198 | ClinicalTrials.gov (NCT01777243) A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis. U.S. National Institutes of Health. | ||||
| Ref 543013 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8255). | ||||
| Ref 524198 | ClinicalTrials.gov (NCT01777243) A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis. U.S. National Institutes of Health. | ||||
| Ref 531012 | PRM-151 (recombinant human serum amyloid P/pentraxin 2) for the treatment of fibrosis. Drug News Perspect. 2010 Jun;23(5):305-15. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.